Coronavirus Antigen Testing Gets Green Light In Germany

Boost for testing volumes and Paul-Ehrlich-Institut role gets industry support

Germany is adjusting the national COVID-19 testing strategy, which from mid-October will include the use of antigen tests.

Paul Ehrlich Institut

Antigen tests for COVID-19 have so far not been part of Germany’s COVID-19 testing strategy, but that will change on 15 October, to add more firepower to the PCR testing regime as the winter flu season kicks in.

Germany’s COVID-19 incidence rate has been rising, as lockdown measures have been eased and people have returned from overseas holidays,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diagnostics

More from Device Area

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By 

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.